NCT04001101: Anti-PD-1 +/- RT for MSI-H Solid Tumors

NCT04001101
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active CNS metastases – see trial for details; Patients with prior receipt of immune checkpoint inhibitor
https://ClinicalTrials.gov/show/NCT04001101

Comments are closed.

Up ↑